Mineralys Therapeutics, Inc. (MLYS)
MLYS moved a median of -0.08% 30 minutes after news, and -0.04% by the close. How MLYS actually reacts to news — the realized, point-in-time move the market made, measured across 491 labeled events over the last three years with zero look-ahead.
MLYS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 42% | 475 |
| 30-min | -0.08% | 49% | 491 |
| 60-min | -0.13% | 47% | 491 |
| to close | -0.04% | 49% | 488 |
| Middle 50% of MLYS reactions | -1.20% to +1.25% |
|---|---|
| Median reaction (30-min) | -0.08% |
| Measured reactions | 491 |
Half of all Mineralys Therapeutics, Inc. news events land between -1.20% and +1.25% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How MLYS reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 13 | +0.25% | 62% | -1.06% |
| Rating reiterations | 36 | -0.32% | 36% | +0.38% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how MLYS ranks against every other measured name →
That’s how MLYS usually reacts — get an email when it moves on news →Email me when MLYS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to MLYS's baseline. Nothing else.
Recent MLYS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Mineralys Therapeutics, For: Oct 16 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats | Press release | GlobeNewswire | — | — | |
| Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026 | Press release | GlobeNewswire | +1.29% | +3.91% | |
| Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026 | Press release | GlobeNewswire | -0.56% | -2.84% | |
| Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026 | Press release | GlobeNewswire | -1.00% | -1.58% | |
| Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.65% | +2.65% | |
| Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum | Press release | GlobeNewswire | -1.28% | -2.60% | |
| Mineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026 | Press release | GlobeNewswire | +0.07% | -0.67% | |
| Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.91% | +2.69% | |
| Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.80% | -2.46% | |
| Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference | Press release | GlobeNewswire | -0.61% | -1.56% | |
| Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.47% | -0.93% | |
| Form 10-Q Mineralys Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +4.40% | +7.68% | |
| Form 8-K Mineralys Therapeutics, For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +4.40% | +7.68% | |
| Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +4.40% | +7.68% | |
| Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026 | Press release | GlobeNewswire | -0.17% | +1.15% | |
| Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.58% | -2.04% | |
| Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) | Press release | GlobeNewswire | -1.52% | -0.25% | |
| Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference | Press release | GlobeNewswire | +1.94% | +5.59% | |
| Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026) | Press release | GlobeNewswire | -1.11% | -5.30% | |
| Form 8-K Mineralys Therapeutics, For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | -1.59% | -5.36% | |
| Form 8-K Mineralys Therapeutics, For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | +2.78% | -0.40% | |
| Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock | Press release | GlobeNewswire | -1.59% | -5.36% | |
| Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing | Press release | GlobeNewswire | -1.59% | -5.36% | |
| Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026) | Press release | GlobeNewswire | -0.63% | +0.39% | |
| Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference | Press release | GlobeNewswire | -0.43% | -1.02% | |
| Form 8-K Mineralys Therapeutics, For: May 21 | SEC filing · Form 8-K | SEC EDGAR | +1.49% | -0.76% | |
| Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026) | Press release | GlobeNewswire | -0.51% | -0.04% | |
| Form 10-Q Mineralys Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.27% | +0.58% | |
| Form 8-K Mineralys Therapeutics, For: May 06 | SEC filing · Form 8-K | SEC EDGAR | -0.27% | +0.58% | |
| Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -0.27% | +0.58% | |
| Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.92% | +2.41% | |
| Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference | Press release | GlobeNewswire | +1.37% | -2.40% | |
| Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026 | Press release | GlobeNewswire | +1.41% | +3.13% | |
| Form ARS Mineralys Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.68% | +2.57% | |
| Form DEF 14A Mineralys Therapeutics, For: May 21 | SEC filing · Form DEF | SEC EDGAR | -0.59% | -3.98% | |
| Form DEFA14A Mineralys Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -0.59% | -3.98% | |
| Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer | Press release | GlobeNewswire | +1.61% | -1.68% | |
| Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.55% | -2.46% | |
| Form 10-K Mineralys Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +4.53% | +1.47% | |
| Form 8-K Mineralys Therapeutics, For: Mar 12 | SEC filing · Form 8-K | SEC EDGAR | +4.53% | +1.47% | |
| Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +4.53% | +1.47% | |
| Form 8-K Mineralys Therapeutics, For: Mar 06 | SEC filing · Form 8-K | SEC EDGAR | -0.04% | +7.49% | |
| Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results | Press release | GlobeNewswire | -0.04% | +7.49% | |
| Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026 | Press release | GlobeNewswire | +1.16% | +1.49% | |
| Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight | Press release | PR Newswire | -0.90% | -0.17% | |
| Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.30% | +2.85% | |
| Form S-8 Mineralys Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +0.77% | +0.99% | |
| Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.92% | -5.30% | |
| Form 8-K Mineralys Therapeutics, For: Jan 06 | SEC filing · Form 8-K | SEC EDGAR | -0.39% | +0.51% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the MLYS section they belong to.
Where else MLYS is measured.
MLYS earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Mineralys Therapeutics, Inc.'s median reaction calculated?
Every labeled MLYS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 491 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 49% of MLYS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does MLYS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.